Drug Profile
Peripheral blood mononuclear cell therapy - Beike Biotech
Alternative Names: PBSCLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Beike Biotechnology
- Class Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic foot
Most Recent Events
- 03 Nov 2009 Phase-I/II clinical trials in Diabetic foot in India (IM)